Navigation Links
Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
Date:10/26/2008

WASHINGTON, Oct. 26 /PRNewswire/ -- Sequoia Pharmaceuticals presented positive results today from two studies on SPI-256, a novel investigational HIV protease inhibitor (PI). One study based on an in vitro analysis demonstrates that the mode of interaction of SPI-256 with HIV protease provides a rationale for its high potency and high genetic barrier to resistance. The second study conducted in healthy volunteers demonstrates that SPI-256 is generally safe and well tolerated in humans and is amenable to boosting by pharmacokinetic enhancers (PKEs). The data were presented at the 48th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/46th annual Infectious Diseases Society of America (IDSA) joint meeting held in Washington, D.C.

"Two ongoing significant needs in contemporary HIV therapy are: new agents that have activity against mutant virus and also have a high genetic barrier to developing resistance; and new agents that can boost the pharmacokinetic levels of existing drugs," said Martin Markowitz, MD, professor and clinical director at the Aaron Diamond AIDS Research Center. "These data on SPI-256 look very promising and address the need for new agents with activity against protease inhibitor-resistant virus as well as the development of resistance. I look forward to further advancements and innovations in HIV that will address our needs in the treatment community from a resistance, as well as a PK, point of view."

Data on SPI-256 at this conference

Discovery and in vitro activity of SPI-256

Scientists from Sequoia Pharmaceuticals presented their structure-based approach that led to the development of SPI-256. Prior to discovering SPI-256, Sequoia scientists examined three-dimensional structures of wild-type and drug-resistant mutant HIV proteases bound to selected inhibitors. By analyzing these structures, the Sequoia scientists were able to identify a subset of main-chain and active-site atoms of
'/>"/>

SOURCE Sequoia Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... , May 24, 2013  An international roster of ... May 18, in Santa Monica, Calif. ... lung-sparing therapies for MPM, a rare form of cancer ... the pleura, the lining of the chest. ... Blood Institute, the 3rd Annual International Symposium on Lung-Sparing ...
(Date:5/24/2013)... 2013 China Biologic Products, Inc. (Nasdaq: CBPO, ... plasma-based biopharmaceutical company in China , ... a public announcement issued by Shanghai RAAS Blood Products ... Shenzhen Stock Exchange, that on May 21, 2013, Ms. ... one of the shareholders of the Company, and her ...
(Date:5/24/2013)... 2013 In accordance with Rule 17.1 and Rule ... the United States Exchange Act, Echo Pharma Acquisition Limited ("Royalty ... Corporation (NYSE: ELN). Background On 2 ... offer for the entire of the issued and to be ... Offer").  On 20 May 2013, Royalty Pharma ...
Breaking Medicine Technology:International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9
... division of Wyeth (NYSE: WYE ), presented ... showed that bazedoxifene/conjugated,estrogens reduced the number and severity ... to 80 percent, when compared with placebo. These,data, ... Meeting,also showed that bazedoxifene/conjugated estrogens improved symptoms of,vulvar ...
... study published in the Oct. 1,Journal of Nutrition suggests ... the risk of prostate cancer, Solae notes, giving consumers ... The study, "Soy protein isolate increases urinary estrogens ... risk of prostate cancer,",is believed to be the first ...
Cached Medicine Technology:Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 2Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 3Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens 4Study Suggests Soy Protein May Reduce Prostate Cancer Risk 2
(Date:5/24/2013)... fractional flow reserve (FFR) using pressure wire assessment ... leads to significant changes in the management of ... a study reported at EuroPCR 2013. , The ... strategy at coronary angiography for diagnosis of chest ... assessment of FFR in all the main coronary ...
(Date:5/24/2013)... discovery at Oregon Health & Science University highlights an ... infected with the highly evasive HIV virus that causes ... this unique approach to develop its own HIV vaccine ... animal studies. This latest research finding will be published ... Science . , "A major challenge in ...
(Date:5/24/2013)... CBT News.com recently announced the addition of ... retail automotive industry news organization with 12 years experience in ... join a group that’s so forward-thinking in their approach,” says ... video content is on the rise.” , Atlanta born and ... segued into advertising at Cycle News and Boating World. He ...
(Date:5/24/2013)... American International College of Arts and ... agreement with Old Dominion University (ODU) that ... , The program will permit ODU students ... cell biology course, taught by AICASA’s faculty, for three ... of Antigua (AUA) College of Medicine , students will ...
(Date:5/24/2013)... recommended well-child visits had up to twice the risk ... their visits, according to a study published today in ... study included more than 20,000 children enrolled at Group ... asthma and heart disease were even more likely to ... study. In fact, children with chronic conditions who ...
Breaking Medicine News(10 mins):Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2Health News:AICASA Signs Articulation Agreement with Old Dominion University to Create Study Abroad Program 2Health News:Young children who miss well-child visits are more likely to be hospitalized 2Health News:Young children who miss well-child visits are more likely to be hospitalized 3
... Brand Innovation is offering a custom e-book, "Notes on Nursing" by Florence ... e-book is one in a series of e-books titled I ... C la s s i ... http://www.stinsonbrandinnovation.com/ebooks/SBI_NotesOnNursing.htm , "This is a way we celebrate the vital ...
... survey also finds unique mix of bacteria for each person ... "atlas" of bacterial life on and within the human body ... are a veritable United Nations of germs. , The scientists, ... they like to thrive on and within the body. They ...
... Picture it: One jerk in a bar spends the night ... the evening, the women aren,t receptive to even the nicest ... evolutionary theory. Males increase their fitness by acquiring more mates; ... and therein lies the conflict. Researchers at Binghamton University ...
... mimic parents, language, study finds , THURSDAY, Nov. 5 ... days old cry with intonation patterns that reflect the ... The conclusion drawn by German researchers is that fetuses ... trimester of pregnancy, laying the groundwork for learning language ...
... Seats still ... ... economy recovers from the recession, the province’s health care sector is just one industry taking ... the field and an increased need for nursing care from the province’s aging population. Anyone ...
... House Rules Committee announced that the "rule" for ... put forward by Rep. Brad Ellsworth, D-Ind. that the House ... language, House Democratic leaders hope to address the reluctance of ... , Dr. Charmaine Yoest, President and CEO of ...
Cached Medicine News:Health News:National Nurse Practitioner Week Recognized by STINSON Brand Innovation With Offer of 'Notes on Nursing' e-book 2Health News:Germs Mingle Most on Palms, Feet, Forearms 2Health News:Germs Mingle Most on Palms, Feet, Forearms 3Health News:Mom was right: Nice guys don't always finish last 2Health News:Fetus Learns Intonations of Mother's Tongue 2Health News:Fetus Learns Intonations of Mother's Tongue 3Health News:Practical Nursing Still a Growth Area in BC 2
... Detection Of Serum C-Peptide ... Measurement:, Evaluating patients ... Assisting in the classification ... Differentiating insulin dependent patients ...
Inquire...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
Inquire...
Medicine Products: